The EU Commission opens an investigation into possible anticompetitive disparagement between two pharmaceutical companies (Vifor Pharma / Pharmacosmos)

Antitrust: Commission opens investigation into possible anticompetitive disparagement by Vifor Pharma of iron medicine* The European Commission has opened a formal antitrust investigation to assess whether Vifor Pharma has restricted competition by illegally disparaging its closest – and potentially only – competitor in Europe on the market for intravenous iron treatment, Pharmacosmos. Vifor Pharma's conduct appears to be aimed at hindering competition against its blockbuster high-dose intravenous iron treatment medicine, Ferinject. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “Competition in the pharmaceutical sector is important. It provides access to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission opens an investigation into possible anticompetitive disparagement between two pharmaceutical companies (Vifor Pharma / Pharmacosmos), 20 June 2022, e-Competitions June 2022, Art. N° 107269

Visites 177

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues